Under one in 10 patients that would benefit from obesity jabs such as Wegovy have access to them, states the World Health Organization as it issues its first guidance on the medications.
Considering in excess of 1,000,000,000 people worldwide now classified as obese, it is advocating for more widespread and fairer access to GLP-1 medication.
According to estimates, in excess of 2,000,000,000 will be obese by 2030 if no action is taken.
"The new guidelines recognises that obesity is a long-term condition that can be managed with comprehensive and ongoing treatment," said WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and logistical bottlenecks are major obstacles to universal access to the treatments that can assist patients in reducing substantial weight, explains the body.
Weight-Loss Drug Scarcity
Despite the present most optimistic outlook, the manufacturing of such drugs could only cover about 100 million people – under 10% of eligible patients, according to the WHO.
The advice urges nations and manufacturers to expand access, through approaches like licensing agreements.
The intellectual property rights on the active ingredient – the primary ingredient of a leading brand – is set to lapse in a number of countries in 2026.
The Way Weight-Loss Injections Operate
These medications mimick a body's own hormone to reduce digestion speed, reduce hunger and enhance satiety so individuals consume fewer calories.
Individuals typically start to lose weight after several weeks of beginning the regular doses.
Studies suggests patients may see weight return a year later of stopping the drug, because their normal hunger come back.
To be carrying excess weight elevates your likelihood for experiencing medical conditions, including diabetes, cardiovascular issues, brain attack, and specific malignancies.
Excess weight impacts individuals in every country and was responsible for millions of fatalities worldwide in 2024, as per the health agency.
